Arrowstreet Capital Limited Partnership Increases Stake in Humana Inc. $HUM

Arrowstreet Capital Limited Partnership grew its position in Humana Inc. (NYSE:HUM) by 3,871.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 124,821 shares of the insurance provider’s stock after acquiring an additional 121,678 shares during the period. Arrowstreet Capital Limited Partnership owned about 0.10% of Humana worth $30,516,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Revolve Wealth Partners LLC purchased a new position in shares of Humana during the 4th quarter worth approximately $202,000. LPL Financial LLC grew its holdings in Humana by 7.4% during the first quarter. LPL Financial LLC now owns 35,005 shares of the insurance provider’s stock worth $9,262,000 after acquiring an additional 2,426 shares during the period. Blair William & Co. IL raised its position in Humana by 11.6% in the first quarter. Blair William & Co. IL now owns 4,614 shares of the insurance provider’s stock worth $1,221,000 after acquiring an additional 481 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Humana by 8.4% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,045,849 shares of the insurance provider’s stock valued at $276,732,000 after acquiring an additional 80,923 shares during the period. Finally, Chicago Partners Investment Group LLC acquired a new stake in Humana in the first quarter valued at $329,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Price Performance

Shares of NYSE:HUM opened at $257.97 on Friday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.02 and a current ratio of 2.02. The business’s fifty day moving average price is $262.52 and its two-hundred day moving average price is $257.25. The stock has a market cap of $31.03 billion, a PE ratio of 24.18, a price-to-earnings-growth ratio of 1.51 and a beta of 0.46. Humana Inc. has a one year low of $206.87 and a one year high of $315.35.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, November 5th. The insurance provider reported $3.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.95 by $0.29. The business had revenue of $32.65 billion for the quarter, compared to the consensus estimate of $31.99 billion. Humana had a return on equity of 12.86% and a net margin of 1.02%.The business’s revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the business earned $4.16 earnings per share. On average, analysts forecast that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, December 26th. This represents a $3.54 dividend on an annualized basis and a yield of 1.4%. Humana’s dividend payout ratio (DPR) is 33.18%.

Analysts Set New Price Targets

HUM has been the subject of a number of research analyst reports. Guggenheim reiterated a “buy” rating on shares of Humana in a report on Friday, October 3rd. Royal Bank Of Canada upped their target price on shares of Humana from $283.00 to $322.00 and gave the stock an “outperform” rating in a research report on Thursday, August 21st. Barclays dropped their target price on shares of Humana from $245.00 to $234.00 and set an “equal weight” rating for the company in a report on Tuesday, November 25th. The Goldman Sachs Group decreased their price target on Humana from $235.00 to $215.00 and set a “sell” rating on the stock in a research note on Monday, November 24th. Finally, Bank of America raised their price objective on Humana from $280.00 to $300.00 and gave the company a “neutral” rating in a research note on Friday, October 10th. Nine analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $296.84.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.